Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, will showcase its regional anesthesia and pain management products featuring improved practices during the ESRA Congress in Glasgow, UK, on September 4-7, 2013.
At the ESRA, September 4-7, Teleflex will highlight its diversified range of regional anesthesia and pain management products. The Company will place particular attention upon its newly designed FlexBlockTM catheterization sets, UltraQuikTM peripheral nerve block needles and the ambIT® PCA pump.
The FlexBlockTM catheterization sets provide clinicians with an echogenic stimulating / non-stimulating needle and the option of ultrasound techniques. The FlexBlock catheter’s unique design offers a combination of ultrasound visibility, flexibility, excellent kink-resistance and a catheter tip that is designed to provide a predictable spread of anesthetic.
Arrow brand clinician inspired UltraQuikperipheral nerve block needles are designed to help increase overall block success when performing single-shot peripheral nerve blocks using ultrasound. To make it as straightforward as possible to identify the needle under ultrasound, the distal end of the needle cannula has five grooved rings.
The ambIT PCA pump ambulatory pain control systems for post-operative pain management from Summit provide flexible, accurate and safe therapy-specific configurations at the lowest cost-in use.
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care, urology and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Limerick, PA, Teleflex employs approximately 11,500 people worldwide and serves healthcare providers in more than 140 countries. Additional information about Teleflex can be obtained from the company's website at teleflex.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
FlexBlock and UltraQuik are trademarks or registered trademarks of Teleflex Incorporated or its affiliates. ©2013 Teleflex Incorporated. All rights reserved.
ambIT® is a trademark of Summit Medical Products, Inc. All rights reserved.
Treasurer and Vice President, Investor Relations
Director Marketing Communications International
|DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentations at the 39th Annual American Society of Regional Anesthetic and Pain Medicine Meeting (2014/4/1)|
|Medgenics to Present Poster at European Society of Gene and Cell Therapy Congress to Highlight Results from Second-Generation Viral Vector ()|
|Medgenics Reports Positive Data with Second-Generation Viral Vectors at European Society of Gene and Cell Therapy Congress ()|
|Teleflex will be Presenting at the 8th Scientific and Annual Meeting of the European Society of Coloproctology (ESCP) ()|
|Teleflex Will Focus on New ‘Care at Home’ Intermittent Catheter Systems at 52nd Annual Scientific Meeting of the ISCOS (International Spinal Cord Society) ()|
|EECP Therapy Receives Class lla Recommendation in European Society of Cardiology Guidelines for the Management of Stable Coronary Artery Disease (2013/9/9)|
|Portola Pharmaceuticals Announces Presentation of Preclinical Data on Andexanet Alfa (PRT44545), Factor Xa Inhibitor Antidote, at 2013 European Society of Cardiology Congress (2013/8/29)|
|Study Evaluating Eculizumab (Soliris®) in Preventing Antibody-Mediated Rejection (AMR) in Kidney Transplant Recipients Presented at the European Society for Organ Transplantation (ESOT) Annual Congress (2013/9/10)|
|Palatin Technologies to Present at the 16th Congress of the European Society for Sexual Medicine (2014/1/30)|
|Teleflex to Showcase Urological Products at the European Association of Urology’s 29th Annual Congress (2014/4/8)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.